Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Melphalan

Review the clinical trials studying melphalan on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 49

Dinutuximab with Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children with Newly Diagnosed High Risk Neuroblastoma
Status: Active
Location: 149 locations
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Status: Active
Location: 100 locations
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
Status: Active
Location: 17 locations
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Status: Active
Location: 21 locations
A Study of Pembrolizumab plus Local Chemotherapy using Isolated Limb Infusion (ILI) for Patients with Sarcoma in the Arm or Leg
Status: Active
Location: 7 locations
Melphalan with or without Siltuximab for the Treatment of Patients with Multiple Myeloma Undergoing an Autologous Stem Cell Transplant
Status: Active
Location: 7 locations
Minimal Residual Disease-Guided Treatment with or Without Autologous Hematopoietic Cell Transplantation and Teclistamab for Patients with Multiple Myeloma, The MASTER-2 Trial
Status: Active
Location: 7 locations
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Location: 4 locations
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 4 locations
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Status: Active
Location: 5 locations
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Status: Active
Location: 3 locations
Orca Q Stem Cells for the Treatment of Pediatric Patients with Leukemia
Status: Active
Location: 4 locations
Immunosuppression-Free Regulatory T Cell Graft-Engineered Haploidentical Donor Stem Cell Transplant for the Treatment of Relapsed/Refractory or Ultra High Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Location: 3 locations
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease
Status: Active
Location: 2 locations
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Status: Active
Location: 5 locations
Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin With or Without Autologous Stem Cell Transplantation for the Treatment Relapsed or Refractory Multiple Myeloma or Newly Diagnosed, High Risk Multiple Myeloma
Status: Active
Location: 2 locations
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed/Refractory Hematologic Malignancies or High Risk Solid Tumors
Status: Active
Location: 2 locations
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients with High-Risk Neuroblastoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Reduced Intensity Conditioning Regimen for the Treatment of Non-Malignant Disorders
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Peritransplant Ruxolitinib for Patients with Primary and Secondary Myelofibrosis
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Haploidentical Stem Cell Transplant with Umbilical Cord Blood Transplant for the Treatment of Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Pembrolizumab Before and After Autologous Stem Cell Transplant for the Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Pre-Transplant Purging and Post-Transplant MRD-Guided Maintenance Therapy with Elranatamab in Patients with High-Risk Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy with or without Total Body Irradiation before Stem Cell Transplant in Treating Patients with Hodgkin or Non-Hodgkin Lymphoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota